drugset / Trial / NCT00776594
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Phase 2
Completed
102 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabGenentech, Inc. · collabRutgers Cancer Institute of New Jersey · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without metastases).
Timeline
- Start
- 2008-10
- Primary completion
- 2014-12
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 unknown | Intravenous |
| Background | Bicalutamide | Other / unclassified | 50 mg | Oral |
| Background | Goserelin | Other / unclassified | 10.8 mg | Subcutaneous |
| Background | Leuprolide | Other / unclassified | 22.5 mg | Intramuscular |